Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases by Mariani, Luciano & Pagliusi, Sonia
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Editorial
Vaccination and screening programs: harmonizing prevention 
strategies for HPV-related diseases
Luciano Mariani*1 and Sonia Pagliusi2
Address: 1Dept. Gynecologic Oncology, Regina Elena National Cancer Institute, Rome, Italy and 2International Public Affairs, Geneva, Switzerland
Email: Luciano Mariani* - luciorm@libero.it; Sonia Pagliusi - sonia_pagliusi@yahoo.com
* Corresponding author    
Abstract
HPV vaccine is an exciting promise of the preventive medicine. Although HPV-immunization
programs still reveal a number of unanswered questions, they represent a novel opportunity for
primary prevention against cervical cancer and other HPV-related pre-neoplastic and neoplastic
diseases. It is reasonable that the short and long-term benefits of vaccination on cervical and vulvo-
vaginal HPV-related pathology will emerge when assuring over time a clear and complete
information to the community and harmonizing the prevention strategies. Indeed, HPV-vaccination
programs will require an understanding of new paradigms of infection and cancer control, and thus
will require a rationale integration with the currently operating screening systems.
Editorial
Much effort has been made in the last decades by scien-
tists, epidemiologists, gynecologists, and other profes-
sionals including virologists, pathologists, and
cytologists, in understanding the carcinogenetic pathways
leading to cervical cancer. Consequently, a vast body of
evidence has emerged indicating that the necessary cause,
although not sufficient, for the development of cancer of
the uterine cervix is the persistence of high-risk Human
papillomavirus (HPV) genital infections [1-3]. This scien-
tific knowledge has been translated into useful diagnostic
tools to detect, and eventually treat, life threatening infec-
tions (such as the viral test) and, more recently, to the
development and launching of preventive HPV-vaccines.
Overall the disease burden attributable to HPV is signifi-
cant, with more than 5% of all cancers worldwide attrib-
uted to such infections [4]. Thus the primary prevention
of cervical cancer through HPV vaccination is viewed as an
important breakthrough in public health. Although HPV-
immunization programs still reveal a number of unan-
swered questions and some author stressed the necessity
of prudence and caution [5,6], they represent a novel
opportunity for primary prevention against cervical can-
cer and other HPV-related pre-neoplastic and neoplastic
diseases, and will provide important health benefits glo-
bally.
Two HPV-vaccines are commercially available: the quadri-
valent vaccine (GARDASIL™) and the bivalent vaccine
(CERVARIX™), made by DNA recombinant techniques
using expression systems based on Yeast and Baculovirus,
respectively (see Table 1, based on X. Bosch [7], M. Stanley
[8], L. Rambout [9]). These HPV-vaccines are constituted
of subunits of the L1 viral protein assembled into struc-
tures called virus-like particles (VLPs) which are not infec-
tious, nor oncogenic. Both vaccines protect against HPV
types 16 and 18, that are together responsible for over
70% of the squamous and glandular cervical cancers
[10,11], as well as other genital and peri-genital (vulva,
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Table 1: Vaccines characteristics and outcomes (randomized clinical trials)
Name ™ GARDASIL CERVARIX
L1 VLP antigens HPV 6 (20 mg) HPV 16 (20 mg)
HPV 11 (40 mg) HPV 18 (20 mg)
HPV 16 (40 mg)
HPV 18 (20 mg)
Expression system Saccharomyces cerevisiae Baculovirus
Adjuvant HAAS
aluminium hydroxyphosphate sulphate
ASO4
aluminium hydroxide plus
3-deacylated monophosphoryl lipid A
Dose schedule 0, 2 and 6 months 0, 1 and 6 months
PHASE III RANDOMIZED TRIALS
Name FUTURE I (13) and II (14)
Females United to Unilaterally
Reduce Endo/Ectocervical Disease
PATRICIA (16)
PApilloma TRIal against Cancer
In young Adults
Years of recruitment 2002–2003 2004–2005
Age of recruited subjects 16–26 15–25
Enrolled women 20,583 18,644
No. of sexual partners ≤4 ≤6
Random comparator Placebo
(225 or 450 μg of aluminum)
Hepatitis A vaccine
IMMUNOLOGIC RESPONSE
Seroconversion ~100% ~100%
Serologic detection method cLIA * binding ELISA
Immunogenicity Established Established
Immune memory at 6 (5?) yrs Established Not reported
CLINICAL RESPONSE
Follow-up 3 years 15 months (interim analysis)
Prophylactic efficacy
HPV 16 CIN2/3+ Established Established
HPV 18 CIN2/3+ Established Positive trend
HPV 16/18 VIN3 Established Not reported
HPV 16/18 VaIN3 Established Not reported
6/11 genital warts Established Not a target
Tolerability Well tolerated Well toleratedJournal of Experimental & Clinical Cancer Research 2008, 27:84 http://www.jeccr.com/content/27/1/84
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vagina, anus, penis) pre-neoplastic and neoplastic dis-
eases. Some oro-pharynx neoplasias have also been linked
to HPV infections [12,13]. The quadrivalent vaccine pro-
tects additionally against HPV 6 and HPV 11 infections
that are associated to over 90% of anogenital warts and
juvenile respiratory papillomatosis [14,15]. The clinical
efficacy of both vaccines against high grade cervical
intraepithelial neoplasias (CIN2+), as demonstrated in
phase III randomized trials at 5 years [16-19] is close to
100% in HPV-naïve women (per-protocol analysis), but it is
lower in women previously exposed to vaccine-targeted
HPV types at the time of vaccination (modified-intention-to-
treat) [15]. This data highlights the prophylactic nature of
the vaccines, that do not accelerate clearance of viral infec-
tions [20] nor prevent the development of CIN in already
infected women.
The quadrivalent vaccine has been approved by the US
Food and Drug Administration (FDA) and the European
Medical Evaluation Agency (EMEA) in 2006, and since
then has received approval by other regulatory authorities
in over 100 countries. The bivalent vaccine was approved
in Australia and by the EMEA in 2007, and in over 60
countries, while is still awaiting FDA approval. The US-
Advisory Committee on Immunization Practices (ACIP)
and many scientific societies (American College of Obste-
tricians and Gynecologists, American Cancer Society,
Society of Gynecologic Oncologists) recommended that
the organized HPV vaccination programs target females
11 to 12 years of age, when the immunological response
to vaccine is most effective and the HPV-seroprevalence is
very low (i.e. ≤ 3% for HPV-16) [21]. Moreover, catch-up
programs are recommended up to 26 years old women
irrespective of HPV status [22]
Separate studies are evaluating HPV vaccines in women
over the age of 25. The rationale for vaccination of women
over 25 years of age, is that, even though HPV infections
tend to occur at relatively early ages and peak incidence
rates occur between the ages of 15–25 for many oncogenic
infections, the majority of women over 25 years of age
have not been previously infected with HPV-16 and/or
HPV-18 [23].
In most European countries the national public health
authorities, through their government advisory panels
recommended the use of HPV-vaccines in national vacci-
nation programs in order to maximize the public health
benefit. In January 2007 the Italian Health Ministry has
expressed an opinion on papillomavirus vaccination
through its technical-scientific committee (Consiglio
Superiore di Sanità) and stated to offer free vaccine doses
to all Italian girls at 12 years old. In this context, vaccina-
tion should preferentially occur through organized pro-
grams in (multi)cohorts prior to sexual debut (pre HPV-
exposition) or close to it. This setting represents the pri-
mary target population for HPV vaccination in Italy, and
allows for better standardization, a more rigorous moni-
toring of vaccination, and is likely to benefit the commu-
nity nation-wide. This is particularly true when organized
vaccination is compared with the vaccination on an indi-
vidual basis. Opportunistic vaccination is based on a dif-
ferent set of considerations than those used in nation-
wide programs, and the ultimate goal is primarily to pro-
tect and provide benefit to an individual woman, some-
times irrespective of age. Moreover, vaccines should also
be offered in catch-up programs at least to girls up to 16
years of age, which corresponds to the upper limit of the
Italian obligatory school and will facilitate for high cover-
age.
Many issues remain unsolved as we enter the era of HPV-
vaccination against cervical cancer. Although vaccination
has been the single most effective public health interven-
tion to protect people against infectious diseases, it
demands a capillary spread, a high acceptance among the
population, an elevated coverage of the target population
and the certainty of sustainable economic resources over
time. Indeed, we are talking about the most expensive
childhood vaccine proposed for a mass use, which may
translate in the very near future (with the need for a main-
tenance of the screening programs) into higher health
costs. Although religious or ethic reactions against vacci-
nation in adolescents may be take into account (due to
the fear that vaccine will promote early sexual activity or
might encourage risky sexual behavior), data concerning
the parents acceptance are reassuring [24] and mothers are
more pragmatic than we might credit them for [25].
Furthermore, effective introduction of HPV-vaccines will
require an understanding of new paradigms of infection
and cancer control, and will require rationale integration
with the currently operating screening systems. Indeed, at
this moment the main challenges are how to properly
Safety at 6 yrs Established Established
Therapeutic efficacy None None
* competitive Luminex-based immune-assays
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combine the two major preventive tools, HPV vaccination
and cervical screening programs, and how to optimize
overall costs of such strategy.
Cervical cancer screening has indeed showed to be highly
effective as secondary prevention in most Western coun-
tries, although historically it was introduced without any
randomized trials performed so far. Also in Italy due to
organized, and also opportunistic, screening programs
cervical cancer mortality significantly dropped from 8.6/
100,000 in 1980 to 3.7/100,000 in 2002. Although it is
well accepted that secondary prevention will have to con-
tinue in parallel to vaccination, because other high-risk
HPV strains not prevented by vaccination may still cause
cervical cancer, we can predict that screening protocols
will change in the near future, for both vaccinated and
non-vaccinated female populations. Due to the low sensi-
tivity and low reproducibility of cervical cytology, screen-
ing strategies are already changing beyond the innovative
wave of HPV-vaccination. We are moving from a preven-
tion model based on cytology-colposcopy-histology to a
biomolecular model based on virologic detection of HPV
and its molecular interactions with the human host [26-
29]. The rationale is to use the most sensitive test to detect
life threatening HPV-infections as up-front tool to identify
all women at risk for HSIL, followed by a more specific
cytological test (e.g. Pap-test) as triage to avoid unneces-
sary referral to colposcopy. HPV-testing is a highly sensi-
tive and objective molecular tool and, as cervical lesion
rates decrease in response to vaccination, it will maintain
its performance in populations with low-HPV prevalence.
Some mathematical predictive models, within the setting
of an organized cervical screening program, demonstrated
that prophylactic HPV vaccination can reduce cervical
cancer, CIN lesions and other genital HPV-related diseases
[30,31], indicating that the implementation of vaccina-
tion within a national screening program is likely to be
cost-effective. Overall costs of HPV-vaccination will be
balanced by the savings of reduction in disease incidence,
less diagnostic and therapeutic procedures. In addition,
the rationalization of new screening strategies in low
HPV-prevalence settings following HPV vaccination may
allow to reduce costly screening programs, through, for
example, deferring the age of starting screening, lengthen-
ing the time-interval between screening rounds or modu-
lating the proper timing between vaccination and
screening. However, this issue still remains to be resolved
because of the limitations of currently available data. For
instance, the lack of knowledge about the long-term effi-
cacy of HPV vaccines, e.g. the need for further boosts to
promote continued immunologic protection, is the major
uncertainty in the cost-effectiveness analysis of HPV vacci-
nation. Although vaccines administered to a pre-teen
could be sufficient to provide protection for at least 10–15
years, during the greatest risk period for HPV infection,
this issue still represents an obstacle to forecast the most
effective prevention strategy.
Any changes in cervical cancer prevention policies (with
or without vaccination) have to be addressed regarding all
women at risk and, if not broadly accepted, could trans-
late into higher disparities among the various socio-cul-
tural layers of the female population. We should rather
avoid increasing disparities among socio-economic
groups, limiting the benefits of vaccine only to the higher-
income subset of societies. This could be the scenario if
vaccine uptake would be low in pre-teens, with a high-rate
of opportunistic vaccine uptake among older girls (24–26
yrs old) already adhering to national screening recom-
mendations. In this hypothetical scenario, despite high
costs, we would not expect a significant decrease in cervi-
cal cancer mortality and morbidity.
Another contemplated scenario concerns the false sense of
safety produced by the vaccination. Some vaccinated
women may perceive to be fully protected from cervical
cancer and may be less likely to participate in screening
programs. In the United States, it has been hypothesized
that if 50% fewer vaccinated women participate in screen-
ing over a 5 year period following HPV vaccination [32]
there would be 4 missed CIN2-3 among 1000 women.
Moreover, vaccinated women may also perceive to be
totally protected from sexually transmitted diseases other
than papillomavirus, potentially leading to changes in
their sexual behavior and increasing the frequency of
other sexually transmitted Infections.
Considering that full impact of vaccination on cervical
cancer will take many decades to be revealed, our final rec-
ommendations about HPV-vaccination are concerning
practical issues surrounding implementation of these vac-
cines in this moment:
￿ Set-up cost-effective preventive programs combining
vaccination and screening, based on the specific HPV-
prevalence in the corresponding geographical area.
￿ Intensify efforts to implement organized vaccination
programs with high-coverage among HPV-naive girls.
￿ Provide adequate HPV type specific surveillance to mon-
itor any changes in HPV type distribution among the gen-
eral population, to assess the impact of vaccination.
￿ Evaluate cross-protection and HPV type-replacement.
￿ Ensure adequate access to, and links between, vaccina-
tion-registries and screening-registriesJournal of Experimental & Clinical Cancer Research 2008, 27:84 http://www.jeccr.com/content/27/1/84
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￿ Verify the vaccine efficacy in men and in high-risk sub-
sets of patients (HIV, immunosupressed)
Many clinical studies are still ongoing all-around the
world to monitor the health impact of both HPV vaccines
over the longer term and also to verify the economic
impact for each country, concerning the local issues
regarding the dynamic process of vaccination (prevalence,
sexually active population, access to health care, etc.). It is
reasonable [33] that the initial positive public health ben-
efit (short-term analysis) will be most apparent for ano-
genital warts, followed by an increasing benefit over time
for all the other HPV-related diseases. It is important to
consider that all of the above mentioned benefits will
emerge when harmonizing the prevention strategies and
assuring over time a clear and complete information to
the community [34]. Moreover, all stakeholders should
devise correct messages to be communicated to women
who bear the greatest risk of HPV-related cancers.
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